Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat with conditioning regimen for lymphoma stem cell transplant
NCT02701673Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of belinostat in lymphoma, diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and 3 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 30 days. Planned start Jun 2016; status: withdrawn.
02
Drugs
belinostat
03
Conditions
lymphomadiffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)T-cell non-Hodgkin lymphomaBurkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT02701673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02701673.